

27. « Aerosil »

29. —————
 / . . . , . . . // . . . — 2011.
—Bun. 2. — .47-52.

30. Prognostic value of plasma endotoxin levels in patients with cirrhosis /C.C. Chan, S.J. Hwang, F.Y. Lee [et al.]//Scand. J. Gastroenterol. — 1997.
—Vol. 32, 9.—P. 942—945.

31. Williams R. Global challenges in liver disease / R. Williams //Hepatol. — 2006. — Vol. 44. — P. 521—526.

14.09.2012

6'6.22:6'2.035:'59.9.0'8

**V. A. Tumanov, T.P. Garnik, V.M. Frolov, Ya.A. Sotskaya,
O.V. Kruglova**
**EFFICIENCY OF DETOXCIC THERAPY WITH USING MODERN
SILICON ENTEROSORBENTS AT THE PATINTS WITH HEPATIC
CIRRHOSIS**

Key words: hepatic cirrhosis, enterosorbition, White coal» (aerosil), treatment.

Efficiency of enterosorbition at the patients with live cirrhosis was investigated. The application of modern silicon enterosorbent «White coal» (aerosil) in the complex therapy of the patients with HC provided achievement of remission chronic pathological process in liver that is accompanied by a tendency to decrease to average molecule level and circulatory immune complex (CIC) and normalization of the molecular composition CIC.

616.36-002:576.343-57.05.12

,

[28]. , ,
() [2, 7, 29]
() [4,

1,5% - ,

0108 009463). » (,

: - - [1, 13, 14].

, (UA/0530/01/01)

65 09.02.2004 . [13].

73
45 , 28 55 (28 , -38,4%
- 61,6%),

(CD3+), (CD22+)-
(CD4+) / (CD8+) -
[22] ().
CD4/CD8,

(271 13.06.2005 . « [8].

« » [23].

III [31]. CD3+, CD4+, CD8+ CD22+
" (-).

() , () [5].

().

Intel Core 2 Duo 3,0 GHz

Microsoft Windows 7, Microsoft Office 2003,
Microsoft Excel Stadia 6.1/prof Srtatistica.

[9].

: (38) (35).

« 13.06.2005 .) » (271 , -

1 3- 400 1 200 , ,
5-7 , ,

(±) , ,

		(=38)	(=35)	
CD3+ % /	69,6±1,6 1,3±0,03	65,4±1,4 1,21±0,03	54,5±1,3* 1,01±0,02*	<0,05 <0,05
CD4+ % /	45,5±1,2 0,86±0,02	45,1±1,1 0,85±0,02	38,9±1,3* 0,72±0,02*	<0,05 <0,05
CD8+ % /	22,5±0,8 0,42±0,01	22,2±0,6 0,41±0,02	21,7±0,9 0,38±0,01	>0,05 >0,1
CD4/CD8	2,02±0,03	2,03±0,05	1,79±0,03*	<0,05
CD22+ % /	21,6±0,9 0,41±0,02	21,1±0,7 0,39±0,03	20,9±0,9 0,38±0,01	>0,05 >0,1
%	65,5±2,2	63,9±1,9	56,4±1,7*	<0,05

CD4+- 1,22 (0,72±0,02)

CD4+- 1,2 (38,9±1,3)%,

CD4+- 1,2 <0,01. CD8+- 1,2 CD22+-

CD8 1,2 1,13

CD4+ 1,2 1,4 1,2

CD4+ / D8.

CD3+ CD4+ CD4/ D8,

(. 2). 1.

CD3+- (

1,2 (1,01±0,02) / , 2.

1,3 ;

1,2 (54,5±1,3)%, 1,3 (<0,01).

(')

- 14.09.2012

The efficiency of succinic acid preparation reamberin at the therapy of the patients with non—alcoholic steatohepatitis (NASH) combined with irritable bowel syndrome (IBS) was investigated. It was set that before treatment along with a presence pain and dyspeptic syndromes with asthenic, asthenic-neurotic or asthenic-depressive disorders took place deviation of immune homeostasis such as cellular immunity. Application of reamberin provided to regress of clinical symptoms of NASH, combined with IBS and normalization of cellular immunity indexes.